US EditionVenus Remedies' VRP-034 receives QIDP designation from US FDA - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Venus Remedies' VRP-034 receives QIDP designation from US FDA - Express Pharma
Venus Remedies has announced that its investigational product, VRP-034, has received Qualified Infectious Disease Product (QIDP) designation from the United States Food and Drug Administration (US FDA) for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults. Developed by Venus Medicine Research Centre (VMRC), VRP-034 is a novel supramolecular cationic formulation of polymyxin B sulphate, designed to …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
